Advancing treatment of acute myeloid leukemia: the future of FLT3 inhibitors

References

• Onai N, Obata-Onai A, Schmid MA, et al. Identification of clonogenic common Flt3+M-CSFR+ plasmacytoid and conventional dendritic cell progenitors in mouse bone marrow. Nat Immunol. 2007;8(11):1207–1216.
   PubMed Web of Science ®Google Scholar
• Kenins L, Gill JW, Hollander GA, et al. Flt3 ligand-receptor interaction is important for maintenance of early thymic progenitor numbers in steady-state thymopoiesis. Eur J Immunol. 2010;40(1):81–90.
   PubMed Web of Science ®Google Scholar
• Takahashi S. Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications. J Hematol Oncol. 2011;4:13.
   PubMed Web of Science ®Google Scholar
• Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209–2221.
   PubMed Web of Science ®Google Scholar
• Schnittger S, Bacher U, Kern W, et al. Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia. Leukemia. 2011;25(8):1297–1304.
   PubMed Web of Science ®Google Scholar
• Schlenk RF, Kayser S, Bullinger L, et al. Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation. Blood. 2014;124(23):3441–3449.
   PubMed Web of Science ®Google Scholar
• Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447.
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Oncology Guidelines. Acute Myeloid Leukemia. 2018. Available from: wwwnccnorg
   Google Scholar
• Boddu PC, Kadia TM, Garcia-Manero G, et al. Validation of the 2017 European leukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes. Cancer. 2018 Dec 6. [Epub ahead of print].
   Web of Science ®Google Scholar
• Sakaguchi M, Yamaguchi H, Najima Y, et al. Prognostic impact of low allelic ratio FLT3-ITD and NPM1 mutation in acute myeloid leukemia. Blood Adv. 2018;2(20):2744–2754.
   PubMed Web of Science ®Google Scholar
• Yalniz F, Kantarjian H, Kadia T, et al. Prognostic significance of baseline FLT3-ITD mutant allele burden in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib. Blood. 2018;132:3983.
   Web of Science ®Google Scholar
• Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a flt3 mutation. N Engl J Med. 2017;377(5):454–464.
   PubMed Web of Science ®Google Scholar
• Nguyen B, Williams AB, Young DJ, et al. FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors. Oncotarget. 2017;8(7):10931–10944.
   PubMedGoogle Scholar
• Stone RM, DeAngelo DJ, Klimek V, et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood. 2005;105(1):54–60.
   PubMed Web of Science ®Google Scholar
• Fischer T, Stone RM, Deangelo DJ, et al.. Phase IIB trial of oral midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. J Clin Oncol. 2010;28(28):4339–4345.
   PubMed Web of Science ®Google Scholar
• Knapper S, Russell N, Gilkes A, et al. A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML. Blood. 2017;129(9):1143–1154.
   PubMed Web of Science ®Google Scholar
• Cortes J, Perl AE, Dohner H, et al. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2018;19(7):889–903.
   PubMed Web of Science ®Google Scholar
• Cortes J, Khaled S, Martinelli G, et al. Quizartinib significantly prolongs overall survival in patients with FLT3-internal tandem duplication–mutated (MUT) relapsed/refractory AML in the phase 3, randomized, controlled quantum-r trial. Presented at: 2018 EHA Congress; 2018 Jun 14;Stockholm, Sweden. Abstract LB2600;2018.
   Google Scholar
• Perl AE, Altman JK, Cortes J, et al. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. Lancet Oncol. 2017;18(8):1061–1075.
   PubMed Web of Science ®Google Scholar
• Fathi AT. Emergence of crenolanib for FLT3-mutant AML. Blood. 2013;122(22):3547–3548.
   PubMed Web of Science ®Google Scholar
• Cortes J, Kantarjian H, Kadia TM, et al. Crenolanib besylate, a type 1 pan-FLT3 inhibitor, to dermonstrate clinical activity in mulitply relapsed FLT3-ITD and D835 AML. J Clin Oncol. 2016;34(15):7008.
   Web of Science ®Google Scholar
• Smith CC, Lin K, Stecula A, et al. FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors. Leukemia. 2015;29(12):2390–2392.
   PubMed Web of Science ®Google Scholar
• Smith CC, Wang Q, Chin CS, et al. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature. 2012;485(7397):260–263.
   PubMed Web of Science ®Google Scholar
• Williams AB, Nguyen B, Li L, et al. Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors. Leukemia. 2013;27(1):48–55.
   PubMed Web of Science ®Google Scholar
• Baker SD, Zimmerman EI, Wang YD, et al. Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia. Clin Cancer Res. 2013;19(20):5758–5768.
   PubMed Web of Science ®Google Scholar
• Christine M, Ferng T, Canaani J, et al. Ras mutations are the dominant mechanism of secondary resistance to gilteritinib therapy for relapsed/refractory FLT3-mutated AML.Presented at: 2018 EHA Congress; 2018 Jun 14-17; Stockholm, Sweden; 2018.
   Google Scholar
• Ivey A, Hills RK, Simpson MA, et al. Assessment of minimal residual disease in standard-risk aml. N Engl J Med. 2016;374(5):422–433.
   PubMed Web of Science ®Google Scholar
• Loken MR, Alonzo, T. A., Pardo L, et al. Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from children’s oncology group. Blood. 2012;120(8):1581–1588.
   PubMed Web of Science ®Google Scholar
• Rollig C, Serve H, Huttmann A, et al. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. Lancet Oncol. 2015;16(16):1691–1699.
   PubMed Web of Science ®Google Scholar
• Ravandi F, Cortes JE, Jones D, et al. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol. 2010;28(11):1856–1862.
   PubMed Web of Science ®Google Scholar
• Serve H, Krug U, Wagner R, et al. Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial. J Clin Oncol. 2013;31(25):3110–3118.
   PubMed Web of Science ®Google Scholar
• Levis M, Ravandi F, Wang ES, et al. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood. 2011;117(12):3294–3301.
   PubMed Web of Science ®Google Scholar
• Stone R, Mandrekar SJ, Sanford B, et al. The addition of midostaurin to standard chemotherapy decreases cumulative incidence of relapse (CIR) in the international prospective. Blood. 2017;130:2580.
   Google Scholar
• Altman JK, Foran JM, Pratz KW, et al. Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia. Am J Hematol. 2018;93(2):213–221.
   PubMed Web of Science ®Google Scholar
• Pratz K, Cherry M, Altman JK, et al. Preliminary results from a phase 1 study of gilteritinib in combination with induction and consolidation chemotherapy in subjects with newly diagnosed acute myeloid leukemia. Blood. 2017;130:722.
   PubMed Web of Science ®Google Scholar
• Wang ES, Tallman MS, Stone RM, et al. Low relapse rate in younger patients < 60 years old with newly diagnosed FLT3-mutant acute myeloid leukemia (AML) treated with crenolanib and cytarabine/anthracycline chemotherapy. Blood. 2017;130:566.
   Web of Science ®Google Scholar
• Jongen-Lavrencic M, Grob T, Hanekamp D, et al. Molecular minimal residual disease in acute myeloid leukemia. N Engl J Med. 2018;378(13):1189–1199.
   PubMed Web of Science ®Google Scholar
• Levis MJ, Perl AE, Altman JK, et al. A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations. Blood Adv. 2018;2(8):825–831.
   PubMed Web of Science ®Google Scholar
• Novartis. Midostaurin (Rydapt) Product Information sheet. 2017.
   Google Scholar
• Larson RA, Mandrekar SJ, Sanford B, et al. An analysis of maintenance therapy and post-midostaurin outcomes in the international prospective randomized placebo-controlled double-blind (CALGB 10603/RATIFY (Alliance)) for newly diagnosed acute myeloid leukemia (AML) patients with FLT3 mutations. Blood. 2017;130:145.
   Web of Science ®Google Scholar
• Brunner AM, Li S, Fathi AT, et al. Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission. Br J Haematol. 2016;175(3):496–504.
   PubMed Web of Science ®Google Scholar
• Burchert A, Bug G, Finke J, et al. Sorafenib as maintenance therapy post allogeneic stem cell transplantation for FLT3-ITD positive AML: results from the randomized double-blind placebo-controlled multicentre sormain trial. Blood Cancer J. 2018;132:661.
   Google Scholar
• Maziarz R, Patnaik M, Scott BL, et al. Radius: a phase 2 randomized trial investigating standard of care ±/- midostaurin after allogeneic stem cell transplant n FLT3-ITD mutated AML. Blood. 2018;132:662.
   PubMed Web of Science ®Google Scholar
• Ravandi F, Alattar ML, Grunwald MR, et al. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood. 2013;121(23):4655–4662.
   PubMed Web of Science ®Google Scholar
• Muppidi MR, Portwood S, Griffiths EA, et al. Decitabine and sorafenib therapy in flt-3 itd-mutant acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015;15(Suppl):S73–S79.
   PubMed Web of Science ®Google Scholar
• Ueno Y, Mori, M, Kamiyama Y, et al. Gilteritinib (ASP2215), a novel flt3/axl inhibitor: preclinical evaluation in combination with Azacitidine in Acute Myeloid Leukemia. Abstract #2830 Presented at the ASH Annual Meeting and Exhibition;2016 Dec 4; San Diego, California; 2016.
   Google Scholar
• Rautenberg C, Nachtkamp K, Dienst A, et al. Sorafenib and azacitidine as salvage therapy for relapse of FLT3-ITD mutated AML after allo-SCT. Eur J Haematol. 2017;98(4):348–354.
   PubMed Web of Science ®Google Scholar
• Fathi AT, Blonquist TM, Hernandez D, et al. Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation. Cancer. 2018;124(2):306–314.
   PubMed Web of Science ®Google Scholar
• Diab S, Abdelaziz AM, Li P, et al. Dual inhibition of Mnk2 and FLT3 for potential treatment of acute myeloid leukaemia. Eur J Med Chem. 2017;139:762–772.
   PubMed Web of Science ®Google Scholar
• Czardybon W, Windak R, Golas A, et al. A novel, dual pan-PIM/FLT3 inhibitor SEL24 exhibits broad therapeutic potential in acute myeloid leukemia. Oncotarget. 2018;9(24):16917–16931.
   PubMedGoogle Scholar
• Andreeff M, Seki T, Zhang W, et al.. Combination of FLT3 inhibitor quizartinib and mdm2 inhibitor milademetan results in greater pre-clinical anti-leukemic activity in FLT3-ITD mutant/p53 wild-type acute myeoid leukemia models;Abstract: PF219 presented at EHA; 2018;Stockholm Sweden.
   Google Scholar
• Konopleva M, Pollyea DA, Potluri J, et al.. Efficacy and biological correlates of response in a phase ii study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016;6(10):1106–1117.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Rausch CR, Benton C, et al. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol. 2018;93(3):401–407.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Pratz KW, Letai A, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018;19(2):216–228.
   PubMed Web of Science ®Google Scholar
• Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002;100(5):1532–1542.
   PubMed Web of Science ®Google Scholar
• Prommersberger S, Jetani H, Danhof S, et al. Novel targets and technologies for CAR-T cells in multiple myeloma and acute myeloid leukemia. Curr Res Transl Med. 2018;66(2):37–38.
   PubMed Web of Science ®Google Scholar
• Durben M, Schmiedel D, Hofmann M, et al. Characterization of a bispecific FLT3 X CD3 antibody in an improved, recombinant format for the treatment of leukemia. Mol Ther. 2015;23(4):648–655.
   PubMed Web of Science ®Google Scholar
• Wang Y, Xu Y, Li S, et al. Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells. J Hematol Oncol. 2018;11(1):60.
   PubMed Web of Science ®Google Scholar
• Assi R, Kantarjian H, Ravandi F, et al. Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors. Curr Opin Hematol. 2018;25(2):136–145.
   PubMed Web of Science ®Google Scholar
• Jetani H, Garcia-Cadenas I, Nerreter T, et al. CAR T-cells targeting FLT3 have potent activity against FLT3(-)ITD(+) AML and act synergistically with the FLT3-inhibitor crenolanib. Leukemia. 2018;32(5):1168–1179.
   PubMed Web of Science ®Google Scholar
• Reiter K, Polzer H, Krupka C, et al. Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia. Leukemia. 2018;32(2):313–322.
   PubMed Web of Science ®Google Scholar